CAR T-Cell Agents for MCL and Indolent Lymphoma

Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discusses her recent presentation around chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) and indolent lymphomas.

Transcription:

0:07 | So, I presented the updates on car T cell therapy in patients with mantle cell and indolent lymphoma, and currently mantle cell lymphoma. We have CD19 CAR T brexucabtagene

approved for relapsed refractory disease based on the ZUMA-2 study, showing an overall response rate of 93% and a complete response rate of 67%. In indolent lymphomas, we have CD19 CAR-T cell therapy approved for patients with relapsed refractory follicular lymphoma based on the ZUMA-5 study, and that shows an overall response rate of 94% a CR rate of almost 80% and durable response with the latest follow up.

0:45 |Another thing that was highlighted in the presentation is that studies are ongoing with other CAR T products across mantle cell and follicular lymphoma. And 1 very interesting combination type of approach that's moving forward in mantle cell lymphoma is the combination of BTK inhibitor, particularly Ibrutinib with CD19 CAR T. Ibrutinib may enhance the activity of CD19 CAR T-cell therapy or CAR T-cell therapy in general, because it shifts the immune response towards a TH1 [or] T-helper 1 type response, which is involved in cytotoxic effector response against cancer that in combination with an impact on the immune microenvironment may help make CAR T-cell therapy more effective and potentially mitigate cytokine release.

1:37 | So, there's a lot of interesting things going on in the mantle and indolent lymphoma space to take our current CAR T products, hopefully expand where they can be used, move them into earlier line settings and move forward with rational combinations to make our therapies more effective and less toxic.